Outsourced AstraZeneca blockade not an issue for local COVID vaccine rollout

EU's decision to block 250,000 doses of AstraZeneca vaccine to Australia not an issue for covid vaccine rollout thanks to CSL local production

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Countries are holding on tight to their locally produced COVID-19 vaccines. As reported by ABC News, Italy and the European Union pulled the handbrake on the 250,000 AstraZeneca Plc (LSE: AZN) doses bound for Aussie shores. Australian politicians have stated that this is not an issue for our COVID-19 vaccine rollout.

As countries globally rush to get their hands on an approved vaccine, tensions have developed. Considering it is a potential ticket to returned economic growth, some are prioritising their own jurisdictions first and foremost.

CSL share price represented by hand in blue glove picks out a vial labelled 'covid-19 vaccine' from a row of vials

Image source: Getty Images

Not an issue for our vaccine rollout

Australian Health Minister Greg Hunt remarked that this decision by the EU would not impact Australia's COVID vaccine rollout:

This is one shipment from one country. This shipment was not factored into our distribution plan for the coming weeks. Domestic production starts with 1 million per week of deliveries from late March and is on track.

NSW Premier Gladys Berejiklian commented on the news this morning, emphasising the critical nature of local production:

I think what it demonstrates is the importance of us having a local supply. In the future, there will be supply issues. You need lots of jabs to be vaccinated properly, and therefore it's really important for us to be able to have our local supply.

The local supply these ministers refer to is coming from Australian-based CSL Ltd (ASX: CSL). Despite the emphasised importance of its operations this morning, the CSL share price is trending 2.6% lower. The biotech giant has now fallen for four consecutive sessions, erasing 8% in 4 days.

Domestic production of the AstraZeneca vaccine by CSL was expected to begin in early March. The company's production is anticipated to yield around 1 million doses per week by the end of March.

Ironic timing as first AstraZeneca vaccine administered

The EU's decision to block the 250,000 vaccines comes at an ironic time, as the first AstraZeneca dose was administered in Australia today.

An estimated 40 frontline staff at the Murray Bridge Hospital in South Australia will have received the vaccine by the end of the day.

Premier Berejiklian also mentioned that she believed media coverage should pivot to reporting on the number of vaccines administered rather than the number of new cases.

Furthermore, with the COVID vaccine rollout underway, the premier urged for the reopening of borders. Otherwise, she said, Australia could be left in the dust economically.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Child investor of ASX shares sitting alongside homemade money-making machine.
52-Week Lows

Are these 3 ASX shares at 52-week lows going cheap?

These ASX All Ords shares have tumbled over 12 months to new 52-week lows. Should you buy?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rare green day for investors this Tuesday.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Broker Notes

3 ASX 200 shares at 52-week lows: Buy, hold, or sell?

These ASX 200 shares have experienced significant falls over the past 12 months. Is there value here?

Read more »

Percentage sign with a rising zig zaggy arrow representing rising interest rates.
Share Market News

ASX 200 resilient in face of latest RBA interest rate increase

ASX 200 investors had widely been expecting the RBA to increase interest rates again today.

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
Broker Notes

Buy, hold, sell: BHP, CSL, and Woodside shares

Let's see if analysts are bullish or bearish on these giants.

Read more »

Frustrated and shocked business woman reading bad news online from phone.
Share Fallers

Why New Hope, Pepper Money, Pro Medicus, and Reece shares are falling today

These shares are having a tough time on Tuesday. But why?

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Challenger, Meeka Metals, Vulcan Energy, and West African Resources shares are rising today

These shares are having a good session on Tuesday. But why?

Read more »

Worried woman calculating domestic bills.
Financial Shares

Pepper Money shares plunge 10% after Challenger slashes takeover offer

The revised proposal comes just over a month after the original takeover approach sparked a strong rally in Pepper’s share…

Read more »